Cereno Scientific’s Board, management and scientific advisors have subscribed warrants within the framework of the incentive programs
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that members of the company's Board and management as well as scientific advisors have signed warrants within the framework of the incentive programs that were introduced at the extraordinary general meeting held on September 14, 2023.“With the company's upcoming data quality control of CardioMEMS in the Phase II study with CS1 in PAH during Q4 2023, which also gives us the opportunity to report early efficacy data, it is a strong statement